Product: VEGFR1 Antibody
Catalog: AF6204
Description: Rabbit polyclonal antibody to VEGFR1
Application: WB IF/ICC IHC-P IHC-F
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit, Dog
Mol.Wt.: 180 kDa; 151kD(Calculated).
Uniprot: P17948
RRID: AB_2835085

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC-f 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(91%), Bovine(91%), Horse(91%), Rabbit(91%), Dog(91%)
Clonality:
Polyclonal
Specificity:
VEGFR1 Antibody detects endogenous levels of total VEGFR1.
RRID:
AB_2835085
Cite Format: Affinity Biosciences Cat# AF6204, RRID:AB_2835085.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

EC 2.7.10.1; FLT 1; FLT; Flt-1; FLT1; Fms like tyrosine kinase 1; Fms related tyrosine kinase 1; Fms related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); Fms related tyrosine kinase 1 vascular endothelial growth factor/vascular permeability factor receptor; Fms-like tyrosine kinase 1; FRT; Soluble VEGF receptor 1 14; Soluble VEGFR1 variant 2; Soluble VEGFR1 variant 21; Tyrosine protein kinase FRT; Tyrosine protein kinase receptor FLT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor vascular permeability factor receptor; Vascular permeability factor receptor 1; Vascular permeability factor receptor; VEGFR 1; VEGFR-1; VEGFR1; VGFR1_HUMAN;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P17948 VGFR1_HUMAN:

Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC).

Description:
Oncogene FLT belongs to the src gene family and is related to oncogene ROS (MIM 165020). Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. The sequence structure of the FLT gene resembles that of the FMS gene (MIM 164770); hence, Yoshida et al. (1987) proposed the name FLT as an acronym for FMS-like tyrosine kinase.
Sequence:
MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
91
Horse
91
Bovine
91
Dog
91
Rabbit
91
Zebrafish
56
Chicken
45
Sheep
0
Xenopus
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P17948 As Substrate

Site PTM Type Enzyme
T218 Phosphorylation
T222 Phosphorylation
T255 Phosphorylation
T265 Phosphorylation
S267 Phosphorylation
K306 Methylation
Y383 Phosphorylation
Y388 Phosphorylation
T404 Phosphorylation
K410 Ubiquitination
T588 Phosphorylation
T599 Phosphorylation
T618 Phosphorylation
S631 Phosphorylation
T633 Phosphorylation
S739 Phosphorylation
S742 Phosphorylation
S743 Phosphorylation
Y745 Phosphorylation
T747 Phosphorylation
T751 Phosphorylation
Y794 Phosphorylation P17948 (FLT1)
Y815 Phosphorylation
K831 Methylation
Y911 Phosphorylation
Y914 Phosphorylation P17948 (FLT1)
Y920 Phosphorylation
K932 Methylation
Y1048 Phosphorylation
Y1053 Phosphorylation
K1064 Ubiquitination
K1153 Methylation
Y1169 Phosphorylation P17948 (FLT1)
S1197 Phosphorylation
S1199 Phosphorylation
K1202 Ubiquitination
S1205 Phosphorylation
S1207 Phosphorylation
Y1213 Phosphorylation P17948 (FLT1)
Y1242 Phosphorylation P17948 (FLT1)
Y1309 Phosphorylation P17948 (FLT1)
Y1327 Phosphorylation P17948 (FLT1)
Y1333 Phosphorylation P17948 (FLT1)

PTMs - P17948 As Enzyme

Substrate Site Source
P17948 (FLT1) Y794 Uniprot
P17948 (FLT1) Y914 Uniprot
P17948 (FLT1) Y1169 Uniprot
P17948 (FLT1) Y1213 Uniprot
P17948 (FLT1) Y1242 Uniprot
P17948 (FLT1) Y1309 Uniprot
P17948 (FLT1) Y1327 Uniprot
P17948 (FLT1) Y1333 Uniprot

Research Backgrounds

Function:

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.

PTMs:

N-glycosylated.

Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation.

Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Endosome.
Note: Autophosphorylation promotes ubiquitination and endocytosis.

Secreted.

Secreted.

Secreted.

Cytoplasm.

Cytoplasm.

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC).

Subunit Structure:

Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR. Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1, PIK3R1, PLCG, PSEN1 and PTPN11. Probably interacts also with PTPRB. Interacts with RACK1. Identified in a complex with CBL and CD2AP.

Family&Domains:

The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFA binding.

Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Immune diseases > Rheumatoid arthritis.

References

1). Zhang Q et al. Thymidine phosphorylase promotes malignant progression in hepatocellular carcinoma through pentose Warburg effect. Cell Death & Disease 2019 Jan 17;10(2):43 (PubMed: 30674871) [IF=9.0]

Application: WB    Species: human    Sample: PLC-PRF-5 cells

Fig. 3| Enzymatic metabolism of extracellular dT regulated by thymidine phosphorylase (TP)affects tumor functions related to vasculogenic mimicry (VM) formation in hepatocellular carcinoma cells..e Western blot analysis of the expression levels of VE–Cad, vascular endothelial growth factor receptor 1 (VEGFR1), and VEGFR2 influenced by overexpressing TP and adding dT in glucose-free cultured PLC-PRF-5 cells. The ratio of densitometry value to the corresponding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) value was used to indicate the relative protein expression. NG means “No Glucose” (mean ± SD; n = 3 in triplicate; **P < 0.01)

Application: IHC    Species: human    Sample: HCC

Fig. 5 |Twist1 relies on thymidine phosphorylase (TP) to promote hepatocellular carcinoma (HCC) malignant progression. HCC samples were divided into four groups of Twist1/TP (−/−), Twist1/TP (−/+), Twist1/TP (+/−), and Twist1/TP (+/+) according to the Twist1/TP expression levels. D Analysis of the HCC specimens by IHC. VE–Cad, vascular endothelial growth factor receptor 1 (VEGFR1), and VEGFR2 were minimally expressed in the Twist1- and TP-negative expression groups. When Twist1 and TP were individually or both positively expressed, the expression levels of the three marker proteins increased.

2). Meng J et al. Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma. ONCOGENE 2018 Aug 7 (PubMed: 30087438) [IF=8.0]

Application: WB    Species: human    Sample: PLC-PRF-5 cells

Fig. 5| Hsp90β promotes Twist1 nuclear translocation and binding to VE-cadherin promoter to increase VM-related gene networks. eWestern blot analysis of VM and EMT-related markers, including VE-cadherin, VEGFR1, VEGFR2, E-cadherin, Vimentin, MMP2, and MMP9 in PLC-PRF-5 cells overexpressed Hsp90β or under lack of Twist1.

3). Meng J et al. RETRACTED ARTICLE: Hsp90β promotes aggressive vasculogenic mimicry via epithelial–mesenchymal transition in hepatocellular carcinoma. Oncogene 2019 Jan;38(2):228-243 (PubMed: 30087438) [IF=8.0]

4). Imafuku et al. Rat Mesenchymal Stromal Cell Sheets Suppress Renal Fibrosis via Microvascular Protection. Stem Cells Translational Medicine 2019 Nov 1 (PubMed: 31675167) [IF=6.0]

Application: IF/ICC    Species: rat    Sample: Bone marrow cells

Figure 7. Assessment of hepatocyte growth factor (HGF)/vascular endothelial growth factor (VEGF) and their activated receptors in the kidneys following bone marrow mesenchymal stromal cell (BMSC)-sheet transplantation. (A, B): The area of phospho-C-met-positive tubules (black arrow) was significantly higher in the BMSC-sheet group relative to that observed in the ischemia–reperfusion-injury (IRI) group. Scale bar: 50 μm. (C, D): The area of phospho-VEGFR-1-positive tubules (white arrow) was significantly higher in the BMSC-sheet group relative to that observed in the IRI group. Scale bar: 50 μm. (E): In the BMSC-sheet group, phospho-VEGFR-1-positive endothelial cells (white arrowhead) was observed in the medulla; *, p < .05. (F): The level of HGF in kidney tissue tended to be higher in the cell sheet group compared to the IRI group. (G, H): The level of VEGF in kidney tissue and urine was significantly lower in the cell sheet group compared to the IRI group.

5). Chen et al. METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma. Cancer Cell International 2022 Sep 27;22(1):295. (PubMed: 36167542) [IF=5.8]

6). Deng S et al. The regulatory roles of VEGF-Notch signaling pathway on aplastic anemia with kidney deficiency and blood stasis. JOURNAL OF CELLULAR BIOCHEMISTRY 2018 Sep 19 (PubMed: 30230583) [IF=4.0]

Application: WB    Species: human    Sample: bone marrow

FIGURE 1| The expression of VEGF‐Notch signaling pathway related factors (VEGF, VEGFR, Notch‐1, Jagged1, Delta‐like1, and hes1) in AA patients with KB (n = 3). A, Relative mRNA expression. B, Protein brands. C, Relative protein expression.Normal, normal bone marrow tissues (n = 5); AA, bone marrow tissues of AA patients with KB (n = 10). **P < 0.01 vs Normal;*P < 0.05 vs normal. AA, aplastic anemia; KB, kidney‐deficiency and blood‐stasis; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor

7). Jie Zhang et al. Ginkgo biloba extract 761 reduces vascular permeability of the ovary and improves the symptom of ovarian hyperstimulation syndrome in a rat model. Gynecological Endocrinology 2022 Mar 14; (PubMed: 35285758) [IF=2.0]

8). Ai XY et al. Sesquiterpene binding Gly-Leu-Ser/Lys-"co-adaptation pocket" to inhibit lung cancer cell epithelial-mesenchymal transition. Oncotarget 2017 Jul 26;8(41):70192-70203 (PubMed: 29050271)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.